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Introduction {#sec1}
============

Primitive hematopoiesis is the first (transient) wave of emerging hematopoietic cells during embryonic development and generates predominantly primitive erythroid cells, macrophages and megakaryocytes within the blood islands in the yolk sac ([@bib30]). Hematopoietic cells, including definitive hematopoietic stem cells (HSCs), with multi-lineage potential and capacity to engraft and reconstitute the blood system, emerge in the definitive wave of hematopoiesis, and originate from different sites within the embryo proper, including the ventral wall of the dorsal aorta within the aorta-gonad-mesonephros region ([@bib5], [@bib26]). Expression of endothelial markers on early hematopoietic cells demonstrates a direct link of hematopoietic and endothelial cells and a common endothelial progenitor ([@bib3], [@bib5]). Lineage-tracing studies provided further evidence for a specialized hemato-endothelial progenitor cell population ([@bib45]) that was broadly termed hemogenic endothelium (HE). HE originates from mesodermal precursors with functional heterogeneity and distinct primitive and definitive hematopoietic capacities ([@bib6], [@bib7], [@bib39]). HE gives rise to hematopoietic cells through a process called endothelial-to-hematopoietic transition (EHT) ([@bib11]). During EHT, endothelial cells successively lose endothelial signature and acquire the hematopoietic phenotype. These processes are strongly controlled by expression of transcription factors (TFs), which direct key stages of hematopoietic development. Among others, members of the ETS (E-twenty-six) TF family are key regulators in the network that governs hematopoiesis. One of the most important members is Ets-related protein 71 (*E*r*71*; *Etv2*) ([@bib21]), which promotes mesodermal formation ([@bib33]) and hematopoietic development. In addition, *Scl* (*Tal1*) is crucial for development of all hematopoietic lineages in the mouse ([@bib32]) but also indispensable for the establishment of the HE ([@bib19]). However, processes of human embryonic hematopoiesis are still poorly understood and mostly extrapolated from animal models. Thus, the use of human pluripotent stem cells (PSCs) and human induced pluripotent stem cells (hiPSCs), offer a powerful tool for new attractive modeling systems to mimic human ontogenetic processes *in vitro*. Directed differentiation protocols mimic ontogenetic processes by co-cultivation systems and/or addition of morphogens ([@bib6], [@bib17]) at the expense of technically demanding protocols, which can generate multipotent hematopoietic progenitor cells (HPCs) capable of producing myeloid and, to a lesser extent, lymphoid hematopoietic cells. However, *de novo* generation of engraftable hematopoietic stem and progenitor cells (HSPCs) from PSCs produced with these protocols has not been convincingly demonstrated. As alternative approaches, several groups overexpressed single or combinations of key TFs in PSC to further improve efficacy and hematopoietic differentiation capacity ([@bib4]). For example, PSCs were directly converted into endothelial cells with a restricted, pan-myeloid or erythro-megakaryocytic, potential ([@bib12]), or the hematopoietic capacity of HE to produce HSPCs was improved but only in immunodeficient mice *in vivo* ([@bib40]). Although multiple protocols demonstrated the feasibility of hPSC differentiation toward HE and HPCs, hematopoietic *in vitro* differentiation remains challenging. This is likely due to the complexity of hematopoietic ontogeny and, as a consequence, demanding differentiation protocols. Moreover, the challenge to generate HPCs and, especially, HSPCs from iPSCs is already apparent in early stages of hematopoietic differentiation, with the generation of adequate hemato-endothelial progenitor (HEP) cells. HEPs often represent the minority of heterogeneous differentiation cultures and must be purified before hematopoietic specification and yet the yield of HEPs and consequently HPCs limits the use of iPSC technologies for several complex experimental settings.

In this study, we aimed to establish a defined, efficient, and stepwise hemato-endothelial specification protocol starting from iPSCs. This protocol is based on a combinatorial approach of directed differentiation and inducible, TF-mediated forward programming. In a gain-of-function approach, we unraveled the effect of selected key TFs on hemato-endothelial specification. We further utilized the induced TF expression of the best-performing combination (*SCL*, *LMO2*, *GATA2*, and *ETV2*) in a defined time window to produce large numbers of HEPs, which gave rise to HPCs that were able to generate erythro-megakaryocytes, granulocytes, monocytes/macrophages, and natural killer (NK) cells. Interestingly, our robust protocol did not directly convert iPSCs into HEPs but followed key steps of mesodermal specification, endothelial priming, and a gradual EHT. Thus, our differentiation method mirrors main physiologic hematopoietic processes *in vitro* and will be useful to identify further master regulators of early human hematopoiesis. Moreover, the large amount of *in vitro* generated HEPs, HPCs, and mature hematopoietic cells provides an experimental basis to use this system for disease modeling, drug discovery/screening experiments, and identification of gene regulatory networks.

Results {#sec2}
=======

Identification of TF Combinations for Hemato-endothelial Specification of Human iPSCs {#sec2.1}
-------------------------------------------------------------------------------------

Several TFs have been described as master regulators of mesodermal patterning, including both endothelial and hematopoietic development ([@bib2], [@bib12], [@bib19], [@bib23], [@bib31], [@bib44]). With the aim to establish an inducible and stepwise differentiation protocol to unravel the individual and combinatorial effects of TFs on early hemato-endothelial specification starting from human iPSCs, we analyzed the capacity of four master regulators, namely *SCL*, *LMO2*, *GATA2*, and *ETV2* (SLGE), to generate HEPs ([Figure 1](#fig1){ref-type="fig"}A). The abovementioned TFs were cloned in mono- or bicistronic configurations via 2A-peptide sequences into third-generation doxycycline (Dox)-inducible all-in-one self-inactivating (SIN) lentiviral vectors. The TF cassettes were driven by the improved T11 Tet-responsive promoter element for tightly regulated transgene expression ([@bib14]) ([Figure 1](#fig1){ref-type="fig"}A). The Dox-dependent transactivator rtTA2S-M2 (M2) was constitutively expressed by the human phosphoglycerate kinase promoter. To allow continuous selection against vector/promoter silencing in SLGE-iPSC cultures, M2 was fused via a 2A-peptide sequence to an antibiotic resistance gene (puromycin or zeocin). The resulting vectors ([Figure 1](#fig1){ref-type="fig"}A) were packaged into lentiviral particles and titrated on a self-designed HT1080 reporter cell line for this Dox-inducible vector system ([Figure S1](#mmc1){ref-type="supplementary-material"}A). Vector titers ranged from 7 × 10^7^ to 4 × 10^8^ transducing units/mL ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and were used to transduce a previously described human fibroblast-derived iPSC line (H2E6C) ([@bib15]). We generated 15 different, genetically modified, stable iPSC lines harboring an inducible single TF or combinations of two, three, or four TFs, respectively. Positive genetically modified iPSCs were selected based on antibiotic resistance genes, maintained as monolayer cultures under continuous selection pressure, and propagated in the pluripotent state for 3 days before initiation of differentiation (day −3 to day 0). On day 0, phase I (hemato-endothelial forward programming) was started with a change to differentiation medium and an initial mesodermal priming boost by a high GSK3 inhibitor (CHIR990221) dose. After mesodermal priming, induction of ectopic TF expression was initiated by addition of Dox on day 1. Cells were differentiated toward the hemato-endothelial lineage via TF expression and a mixture of supportive hematopoietic and endothelial cytokines (stem cell factor \[SCF\], thrombopoietin \[TPO\], interleukin-3 \[IL-3\], fibroblast growth factor 2 \[FGF2\], and vascular endothelial growth factor \[VEGF\]) ([Figure 1](#fig1){ref-type="fig"}A). On day 7 (end of phase I), the effect of the different TF/combinations overexpression was assessed based on their potential to induce hemato-endothelial specification. Expression of endothelial markers CD144 and CD73 was used to demarcate angioblast cells, including HEPs (CD144^+^/CD73^--^), from maturating vascular endothelial cells (VECs) (CD144^+^/CD73^+^) that lack hemogenic potential ([@bib6]) ([Figures 1](#fig1){ref-type="fig"}B and 1C). Overexpression of *SCL* or *LMO2* alone generated low percentages of cells with VEC or HEP immunophenotypes. *GATA2* overexpression gave rise to an increased population of VECs, but only a low percentage of HEPs. Remarkably, *ETV2* alone was a strong inducer of endothelial specification. However, these endothelial cells displayed almost uniformly a CD144^+^/CD73^+^ VEC (84.1%) immunophenotype ([Figure 1](#fig1){ref-type="fig"}B). Two-factor combination of *LMO2/SCL* increased the generation of VECs. Furthermore, *LMO2* acted synergistically with *GATA2* and *ETV2* to increase the HEP population from 1.8% (*GATA2* alone) to 4.1% (*LMO2/GATA2*) and 1.3% (*ETV2* alone) to 15.3% (*LMO2/ETV2*) ([Figure 1](#fig1){ref-type="fig"}B). The combination of *ETV2/GATA2* increased the percentage of HEPs to 19.2% compared with *ETV2* alone (1.3%) or *GATA2* alone (1.8%). Similarly, *SCL/GATA2* together increased the HEP population from 0.2% (*SCL* alone) or 1.8% (*GATA2* alone) to 8.0%. Given these synergistic effects of the two-factor combinations, we further investigated the additional effect of three- or four-factor combinations ([Figure 1](#fig1){ref-type="fig"}C). The addition of *LMO2* (*SCL/LMO2/ETV2* and *LMO2/GATA2/ETV2*) had no substantial change on the immunophenotype compared with the two-factor combinations *SCL/ETV2* or *GATA2/ETV2*, respectively. Interestingly, the combination *SCL/LMO2/GATA2* abrogated formation of VECs and gave rise to a population of HEP immunophenotypic cells with low level CD144 expression. Remarkably, *SCL/GATA2/ETV2* together gave rise to a very high percentage of immunophenotypic HEPs (83.5%). This effect was further increased (90.5%) by addition of *LMO2* (*SCL/LMO2/GATA2/ETV2*) ([Figure 1](#fig1){ref-type="fig"}C). These experiments were repeated in three independent differentiations ([Figure 1](#fig1){ref-type="fig"}D). Generation of HEPs was significantly increased in the four-factor combination (*SCL*/*LMO2*/*GATA2*/*ETV2*) compared with all two-factor combinations. Although the differences between the best-performing combinations *SCL*/*GATA2*/*ETV2* and *SCL*/*LMO2*/*GATA2*/*ETV2* to generate HEPs were not significant ([Figure 1](#fig1){ref-type="fig"}D), we concluded SLGE to be the most potent combination to induce hemato-endothelial specification due to the synergistic effects and the increased generation of HEPs of the two-factor combinations with *LMO2*. Therefore, we used the SLGE-iPSCs as starting material for our forward programming and more detailed analyses.Figure 1Hemato-endothelial Specification Potential by Induction of Transcriptional Regulators(A) Schematic vector architecture for ectopic expression of single transcriptional regulators or combinations (*SCL*, *LMO2*, *GATA2*, and *ETV2*) based on a Dox-inducible all-in-one system. These vectors were used to genetically modify and generate stable iPSC lines with subsequent induction of hemato-endothelial specification (phase I).(B and C) Comparison of individual or combinatorial expression of transcriptional regulators on hemato-endothelial specification potential (phase I day 7). Invididual and two-factor combinations are given in (B) and three-/four-factor combinations in (C). Representative flow cytometric analysis of CD144 and CD73 expression are shown. Samples were gated on fluorescence minus one (FMO) controls.(D) Statistical analysis of vascular endothelial (CD144^+^/CD73^+^) or hemato-endothelial (CD144^+^/CD73^--^) potential of all transcriptional regulators/combinations (n = 3 independent differentiations, error bars represent SD). Significance was calculated by one-way ANOVA with Tukey\'s post-hoc test (n.s., not significant; p ≥ 0.05, ^∗∗∗^p \< 0.001).

Generation of Durable Genetically Modified iPSCs with Tightly Regulated Inducible Transgene Expression {#sec2.2}
------------------------------------------------------------------------------------------------------

To validate the inducibility of the SLGE vector system in detail, we performed qRT-PCR analysis and confirmed a strong increase of exogenous *SCL* (2,393- ± 265-fold), *LMO2* (900- ± 46-fold), *GATA2* (164- ± 3-fold), and *ETV2* (166- ± 12-fold) expression upon Dox treatment. However, low expression levels of all four exogenous TF were also detected in the absence of Dox, likely due to some leakiness of the inducible T11 promoter ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Despite slight expression of TFs in the absence of Dox, SLGE-iPSCs maintained expression of typical pluripotency genes (*OCT4* and *NANOG*) and surface markers (TRA-1-60 and SSEA-4) at levels similar to unmodified H2E6C iPSCs or human embryonic stem cells ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). However, Dox-mediated induction of TF overexpression in SLGE-iPSC maintenance cultures was associated with a dramatic loss of expression of these pluripotency markers ([Figures S1](#mmc1){ref-type="supplementary-material"}D and S1E). Furthermore, non-Dox-induced SLGE-iPSCs retained the full ability to differentiate toward endodermal (lumen-lining epithelium), ectodermal (immature neuro-epithelium), and mesodermal (cartilage) cells as visualized in a teratoma formation assay ([Figure S1](#mmc1){ref-type="supplementary-material"}F). Altogether, SLGE-iPSCs could be maintained in a pluripotent state for at least 6 months without spontaneous differentiation (data not shown).

SLGE Robustly Directs Hemato-endothelial Specification and Produces HEP Cells in a Dox-Dependent Manner {#sec2.3}
-------------------------------------------------------------------------------------------------------

To evaluate the effect and potential of SLGE-mediated forward programming, we compared the capacity of SLGE-iPSCs to generate hemato-endothelial cell types with and without ectopic SLGE expression. SLGE-iPSCs were differentiated as described in [Figure 1](#fig1){ref-type="fig"}A and analyzed daily by flow cytometry. The differentiation progress of phase I was monitored based on the expression of the common endothelial surface marker CD144 and the VEC marker CD73 under SLGE induction (+Dox, green) or without SLGE induction (--Dox, red) ([Figure 2](#fig2){ref-type="fig"}A). CD144 expression was notably increased by day 2 of SLGE induction and the cell population was almost completely CD144^+^ by day 7. The vast majority of these cells remained negative for CD73, indicating the presence of HEPs. The early endothelial marker CD309 (VEGFR2/KDR) was notably upregulated already on day 2 of SLGE-mediated differentiation (78.4%) compared with day 1 (4.1%) ([Figure S2](#mmc1){ref-type="supplementary-material"}A). Kinetic analysis revealed that CD235a, an erythroid marker that is also expressed on a mesodermal subpopulation fated to primitive hematopoietic progenitors ([@bib39]), was first expressed on day 3 in a subset of cells (40.7%) in the CD144^+^/CD73^--^ HEP population ([Figure S2](#mmc1){ref-type="supplementary-material"}B). At this stage, cells were negative for CD43, a marker expressed on emerging hematopoietic cells ([@bib42]). CD43 expression was first detected on day 4 and increased through day 6, especially on CD235a-expressing cells ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The CD235a-expressing subset strongly decreased on day 7 ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Taken together, we obtained a dense, homogeneous monolayer ([Figure 2](#fig2){ref-type="fig"}B) with a HEP-like phenotype (∼89.0% ± 2.0% CD144^+^/CD73^--^) and only a small subpopulation with a VEC immunophenotype (∼5.0% ± 2.4% CD144^+^/CD73^+^) on day 7 ([Figure 2](#fig2){ref-type="fig"}C). Importantly, the overall potential of endothelial differentiation and HEP generation was highly dependent on the induction of SLGE expression. Without Dox, differentiated cells exhibited a heterogeneous morphology with tubular-like structures ([Figure 2](#fig2){ref-type="fig"}B) and no substantial upregulation of CD144 or CD73. Only a small population of these cells exhibited a VEC or HEP immunophenotype on day 7 of differentiation (1.6% ± 0.3% or 0.4% ± 0.1%, respectively) ([Figure 2](#fig2){ref-type="fig"}C). Removal of supportive cytokines during phase I increased the VEC population at the expense of HEPs. Mesodermal priming by CHIR, before SLGE induction, was dispensable for efficient HEP generation ([Figure S2](#mmc1){ref-type="supplementary-material"}C). The robustness of the TF-mediated forward programming protocol was shown in 19 independent differentiation experiments that generated an average level of 89.0% ± 7.5% phenotypic HEPs and 7.7% ± 3.9% VECs ([Figure 2](#fig2){ref-type="fig"}D). Phase I day 7 HEPs (SLGE-HEPs) expanded 9.8- ± 2-fold (n = 8) with respect to the initial number of SLGE-iPSCs seeded ([Figure 2](#fig2){ref-type="fig"}E). SLGE-HEPs showed an intermediate CD235a expression, moderately expressed CD34 and were positive for CD117 (c-Kit) ([Figure 2](#fig2){ref-type="fig"}F), indicating an HE-like phenotype ([@bib8]). However, these SLGE-HEPs already expressed the very early hematopoietic marker CD43 but were negative for the pan-hematopoietic marker CD45 ([Figure 2](#fig2){ref-type="fig"}F).Figure 2Phase I: Characterization of SLGE-mediated Hemato-endothelial Forward Programming(A) Kinetic immunophenotype analysis of phase I based on the expression of CD144 and CD73 with and without induction (+/--Dox) of SLGE. Percentages of the individual populations are indicated in the same color as the populations.(B) Representative microscopic analysis of SLGE-iPSC phase I day7 with and without induction of SLGE overexpression (+/--Dox). Scale bars, 200 μm.(C) Influence of SLGE induction on HEP (CD144^+^/CD73^--^) and VEC (CD144^+^/CD73^+^) production at phase I day7 (+Dox) (n = 3 independent differentiations, error bars represent SD).(D) Overall yield of Dox-induced SLGE-HEPs (CD144^+^/CD73^--^) and vascular endothelial cells (CD144^+^/CD73^+^) (n = 19 individual differentiations). p values were calculated using unpaired t test. Significance is indicated by asterisks: (^∗∗∗^p \< 0.001).(E) Expansion rate of SLGE-HEPs was calculated with respect to the number of initially seeded iPSCs (n = 8 independent experiments).(F) Surface marker expression of CD144, CD73, CD235a, CD117, CD43, CD45, and CD34 evaluated by flow cytometry. SLGE-HEPs showed an HEP phenotype of CD144^+^/CD73^--^/CD43^+/−^/CD235a^+/--^/CD117^+^/CD34^−/+^/CD45^--^ (gated on FMO).

SLGE-HEPs Generate HPCs {#sec2.4}
-----------------------

Although SLGE-HEPs expressed the early hematopoietic marker CD43, they were not fully committed to the hematopoietic fate at this stage as SLGE-HEPs acquired a VEC immunophenotype (CD144^+^/CD73^+^/CD34^+^) within 7 days of cultivation in EGM2 (endothelial growth medium) without Dox-induced TF expression ([Figure S3](#mmc1){ref-type="supplementary-material"}A). These SLGE-VECs were adherent ([Figure S3](#mmc1){ref-type="supplementary-material"}B), able to form tubular-like structures ([Figure S3](#mmc1){ref-type="supplementary-material"}C) and negative for CD45 under endothelial conditions ([Figure S3](#mmc1){ref-type="supplementary-material"}A). More importantly, hematopoietic cells were generated from SLGE-HEPs by cultivation of dissociated SLGE-HEPs in STEMdiff APEL 2 medium supplemented with supportive cytokines (SCF, TPO, FLT3L, IL-3, and FGF2) for hematopoietic development (phase II: generation of HPCs). Noteworthy, phase II was accomplished in the absence of Dox to avoid ectopic SLGE expression and any potential effects on the progression or the phenotype of generated hematopoietic cells. On day 9 of phase II, cells formed compact clusters with adherent cells loosely connected to the surface. The clusters increased in size and generated numerous round-shaped suspension cells within 5 days of phase II (day 11) ([Figure 3](#fig3){ref-type="fig"}A). During this progression, HEPs successively lost endothelial characteristics and gained a hematopoietic signature. To more closely investigate this process, we monitored the expression kinetics of endothelial (CD144) and hematopoietic (CD45) markers throughout phase II (days 7--11). Initially, SLGE-HEPs were CD144^+^ and expressed CD34 at a low level. From day 7 to 8, CD144^+^ cells showed a notable increase in CD34 expression with subsequent CD144 downregulation, resulting in an almost complete loss of endothelial signature by day 11. In contrast, CD45 expression was strongly upregulated along with CD34 expression by day 8 and peaked on day 10 of phase II. The complete loss of CD144 expression and the gain of CD45 indicated a complete EHT and efficient generation of SLGE-iPSC-derived hematopoietic progenitors (SLGE-HPCs) ([Figure 3](#fig3){ref-type="fig"}B). The generation of CD45^+^/CD34^+^ SLGE-HPCs was very robust (∼60% ± 12%, n = 21) ([Figure 3](#fig3){ref-type="fig"}C) concomitant with a proliferative expansion rate of 3.2 ± 0.66-fold (n = 7) respective to initially seeded SLGE-HEPs ([Figure 3](#fig3){ref-type="fig"}D), and a total expansion rate of ∼30-fold respective to initially seeded SLGE-iPSCs on day −3 of the protocol. Detailed flow cytometric analysis indicated a characteristic HPC phenotype. Noteworthy, these CD45^+^/CD34^+^ cells expressed the HSC-like markers CD43, CD90, and CD49f at high levels, CD235a intermediately, and were negative for lineage markers CD38 and CD45RA ([Figure 3](#fig3){ref-type="fig"}E). Interestingly, this phenotype CD45^+^/CD34^+^/CD38^--^/CD45RA^−^/CD90^+^/CD49f^+^ of SLGE-HPCs was described to characterize multipotential adult HSPCs ([@bib28]). We validated the potential of SLGE-mediated forward programming with two additional previously described iPSC lines, namely hCD34iPSC16 ([@bib1]) and iMSMD-cohet 17 ([@bib27]), which exhibited similar hemato-endothelial and hematopoietic differentiation potentials ([Figure S3](#mmc1){ref-type="supplementary-material"}D). Importantly, also cultivation of SLGE-iPSCs in fully defined StemMACS iPS-Brew XF medium resulted in efficient production of SLGE-HEPs and SLGE-HPCs ([Figure S3](#mmc1){ref-type="supplementary-material"}E).Figure 3Characterization of SLGE-HPCs(A) Schematic representation of phase II, generation of SLGE-HPCs. SLGE-HEPs were seeded into medium supplemented with cytokines supportive for hematopoietic specification, without Dox. Morphologic changes are shown by representative microscopy images on days 9--11 of phase II. Scale bars, 200 μM.(B) Kinetic flow cytometric analysis of endothelial-to-hematopoietic transition phase II (days 7 to 11) for endothelial marker CD144 as well as hematopoietic markers CD45 and CD34.(C) Overall yield of CD45^+^/CD34^+^ SLGE-HPCs (n = 21 independent differentiation experiments).(D) Expansion rate of SLGE-HPCs as calculated with respect to the number of initially seeded SLGE-HEPs (n = 7 independent differentiation experiments).(E) Hematopoietic surface marker expression evaluated by flow cytometric analysis (gates were set based upon FMO controls). Day 11 SLGE-HPCs had a CD45^+^/CD34^+^/CD235a^low^/CD43^+^/CD90^+^/CD49f^+^/CD38^--^/CD45RA^--^ phenotype.

SLGE-Directed Hemato-endothelial Forward Programming Is Tightly Regulated and Shows Intermediate Key Stages of Hemato-endothelial Specification {#sec2.5}
-----------------------------------------------------------------------------------------------------------------------------------------------

To analyze if distinct intermediate developmental stages and embryonic cell types typical for hematopoiesis can be generated with our forward programming protocol, we dissected the entire differentiation progression into different time points according to expression of indicative target genes via qRT-PCR ([Figure 4](#fig4){ref-type="fig"}A). As expected, *OCT4* (black line) expression was highest at the PSC state on day 0 and decreased rapidly until day 3. Expression of the typical mesodermal marker *TBXT* (T; Brachyury; blue, dashed line) peaked on day 1 during mesodermal priming and was quickly downregulated. *KDR* (blue line) expression increased to peak on day 2, was maintained at lower expression levels during phase I, and expression further diminished during phase II. Endothelial gene *CDH5* (CD144; green line) expression was first detected between days 1 and 2 and peaked at the end of phase I on day 7, before rapidly decreasing in phase II. The first hematopoietic marker (*RUNX1*; red line, primer pair specific for all *RUNX1* isoforms) was expressed at lower expression levels already between days 1 and 2 and peaked on day 7 with a second peak in phase II on day 10. Expression of *RUNX1* isoform c (*RUNX1c*, dashed red line), a marker indicating HEP and HPC specification, was strongly upregulated on day 7 of phase I and peaked on day 10 during the EHT process. Thus, expression of major hemato-endothelial markers increased directly after induction of SLGE overexpression, but especially *RUNX1c* expression fully peaked during EHT and hematopoietic specification in the absence of Dox-induced TF expression. To further strengthen the observation that our forward programming protocol mimics *in vivo* ontogeny, we performed RNA sequencing analysis during the first differentiation days ([Figure 4](#fig4){ref-type="fig"}B). After mesodermal priming (phase I day 1), genes characteristic of early mesodermal stages (*EOMES*, *MESP1*, *MIXL1*, and *T*) were upregulated and subsequently downregulated 1 day later. On day 2 of phase I, 1 day after SLGE induction, upregulation of genes associated with early endothelial/angiohematopoietic specification was detected based on RNA sequencing data (e.g., *CDH5*, *ESAM*, *FLI1*, *KDR*, *NRP1*, and *TEK*) ([Figure 4](#fig4){ref-type="fig"}B). qRT-PCR confirmed that expression levels of exogenous SLGE were tightly regulated during differentiation by addition or withdrawal of Dox ([Figure 4](#fig4){ref-type="fig"}C). Importantly, ectopic SLGE expression levels were constantly high-throughput phase I in the presence of Dox and abruptly decreased back to basal expression levels within 1 day after Dox withdrawal on day 8 (phase II) at the beginning of EHT and the production of HPCs.Figure 4Characterization of Intermediate Developmental Stages and Ectopic SLGE Expression during Hemato-endothelial Forward Programming(A) qRT-PCR for endogenous mRNA expression levels of target genes indicative for pluripotency (*OCT4*), mesodermal (*TBXT* and *KDR*), endothelial (*CDH5* \[CD144\]) and hematopoietic (*RUNX1* and *RUNX1c*) stages during the differentiation process. The point of maximum gene expression was set to 1 for each target. Human *ACTB* (β-actin) was used as a housekeeping control and for normalization of target gene expression.(B) Row-scaled heatmap of characteristic mesodermal- or endothelial-associated genes during early stages of phase I (days 0--2) based on RNA sequencing data. Gene ontology based on the Database for Annotation, Visualization and Integrated Discovery (DAVID) or literature ([@bib6]).(C) qRT-PCR for Dox-based regulation of exogenous *SCL*, *LMO2*, *GATA2*, and *ETV2* expression during the differentiation process. Expression levels were normalized to basal expression of non-induced day 0 SLGE-iPSCs and relative to *ACTB* (β-actin) housekeeping gene expression in triplicate samples.

SLGE-HPCs Generate Erythroid, Megakaryocytic, Myeloid, and NK Cells {#sec2.6}
-------------------------------------------------------------------

To demonstrate the hematopoietic potential of SLGE-HPCs, cells were terminally differentiated toward different hematopoietic lineages. SLGE-HPCs produced CD45^−^CD41^+^CD42a^+^CD61^+^ megakaryocytes ([Figure 5](#fig5){ref-type="fig"}A) with large and multi-lobulated nuclei upon stimulation with TPO ([Figure 5](#fig5){ref-type="fig"}B, red arrows). Differentiation with EPO (erythropoietin) gave rise to CD45^--^CD235a^+^ erythroid cells ([Figure 5](#fig5){ref-type="fig"}A) with normoblast-like cell morphology ([Figure 5](#fig5){ref-type="fig"}C). These erythroid cells expressed different globin types ([Figure S4](#mmc1){ref-type="supplementary-material"}A), with embryonic isoforms ζ- and ε-globin, and fetal isoforms γ- and α-globin, as the most prevalent. Adult-type β-globin was only expressed at low levels. Expression of all globin isoforms, including adult globin, was validated by gel electrophoresis of the qRT-PCR products ([Figure S4](#mmc1){ref-type="supplementary-material"}B). In addition, SLGE-HPCs also exhibited myeloid potential. Stimulation with macrophage colony stimulating factor promoted a population of CD45^+^CD11b^+^ myeloid cells ([Figure 5](#fig5){ref-type="fig"}A). This population was divisible into two distinct populations with either classical M2 immunoregulatory macrophage phenotype (CD14^+^/CD163^+^; marked in green) or M1-like polarized macrophage phenotype (CD14^--^/CD163^--^/CD209^--^ and CD86^+^, marked in red). Macrophages showed characteristic cytoplasmatic inclusion and a single, round-shaped nucleus ([Figure 5](#fig5){ref-type="fig"}D). CD45^+^/CD14^--/low^ cells emerged upon differentiation with granulocyte colony stimulating factor ([Figure 5](#fig5){ref-type="fig"}A). These cells expressed the granulocyte marker CD66b (∼6%) and stained positive for CD15 and CD16 at a low level. Despite the low amount of CD66b^+^ cells, cytospin images revealed that a large number of cells exhibited classical granulocytic morphology at different developmental stages (e.g., myelocytes and mature segmented neutrophils; [Figure 5](#fig5){ref-type="fig"}E). For lymphoid differentiation, SLGE-HPCs were co-cultured with OP9-Dll1 stromal cells. This led to generation of a clear population of CD45^+^CD56^+^CD16^--^ NK cells upon cultivation in medium containing FLT3L/IL-7/IL-15 ([Figure 5](#fig5){ref-type="fig"}A). However, we did not detect any T cells under OP9-Dll1 co-culture differentiation conditions (data not shown). Furthermore, progenitor character of phase II day 11 SLGE-HPCs was confirmed in colony-forming cell assays in which cells proliferated and formed all lineage-specific and mixed colonies (CFU-M, CFU-GEMM, CFU-E, CFU-GM, and CFU-G) ([Figure 5](#fig5){ref-type="fig"}F). However, colony-forming potential was biased as most colonies (produced from 1,000 initially seeded cells) were CFU-M (56 ± 9 colonies) and CFU-E (47 ± 19 colonies), whereas CFU-GEMM (10 ± 3 colonies), CFU-GM (7 ± 8 colonies), and CFU-G (8 ± 2 colonies) were less prominent. To investigate SLGE-HPC engraftment function, 2 × 10^6^ SLGE-HPCs were intravenously transplanted into irradiated NSGS mice, but SLGE-HPCs showed no long-term engraftment or reconstitution potential in contrast to cord blood (CB)-HSPCs ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Presence of human SLGE-HPC-related CD45^+^ cells was detected in peripheral blood up to 2 weeks after transplantation in two of three mice, but not at weeks 4, 6, or 8. In contrast to human CB-transplanted mice, SLGE-iPSC-derived hematopoietic cells were not found in bone marrow or spleen 8 weeks post-transplantation ([Figure S4](#mmc1){ref-type="supplementary-material"}D).Figure 5Terminal Differentiation of SLGE-HPCs into Mature Blood Cell Lineages(A) For terminal differentiation, SLGE-HPCs were stimulated with TPO for 14 days (megakaryocytic specification), with EPO for 7 days (erythroid specification), with macrophage colony-stimulating factor (M-CSF) for 7 days (monocytic/macrophage specification), with granulocyte colony-stimulating factor (G-CSF) for 7 days (granulocyte specification), or with FLT3L/IL-7/IL-15 for 14 days in co-cultivation on OP9-Dll1 cells (NK cell specification). Flow cytometry analysis of terminal differentiation for typical surface marker expression for megakaryocytes (CD45^--^, CD41a^+^, CD42a^+^, and CD61^+^), erythroid cells (CD45^--^ and CD235a^+^), macrophages (CD45^+^, CD11b^+^, CD14^+^ or CD14^--^, CD163^+^ or CD163^--^, CD86^+^ or CD86^--^, and CD209^--^), granulocytes (CD45^+^, CD14^--/low^, CD66b^+^, CD15^+^, and CD16^+^) (gates were set according to FMO controls) and NK cells (CD45^+^, CD56^+^, and CD16^--^) (gates were set according to unstained control).(B--E) (B) Cytospins of day 14 differentiated megakaryocytes (red arrows), (C) differentiated erythroid cells, (D) terminally differentiated macrophages, or (E) differentiated granulocytes.(F) Proliferation and multi-lineage differentiation ability of phase II day 11 SLGE-HPCs confirmed by colony-forming assays. Colonies were counted and characterized 14 days after initiation (n = 3 independent experiments).

RNA Sequencing Comparison between CB-HSCs and SLGE-HPCs Reveals Similarities but Also Major Differences {#sec2.7}
-------------------------------------------------------------------------------------------------------

The HSC-like surface immunophenotype (CD45^+^/CD34^+^/CD90^+^/CD49f^+^/CD38^--^/CD45RA^−^), proliferation potential and ability to generate different blood-lineages (including NK cells) suggested a close developmental correlation between SLGE-HPCs and early HSPCs, whereas the incapacity to differentiate into T cells and to engraft into immunodeficient mice also revealed functional and qualitative differences. To unravel the similarities and underlying differences between SLGE-HPCs and CB-HSPCs, we performed whole transcriptome analysis on distinct populations based on a previously described sorting strategy ([@bib28]). SLGE-HPCs and human umbilical CB-HSCs were sorted for CD45^+^/CD34^+^/CD38^--^/CD45RA^−^/CD90^high^/CD49f^high^-expressing cells ([Figure S5](#mmc1){ref-type="supplementary-material"}) and compared with SLGE-iPSCs (TRA-1-60^+^/SSEA4^+^) and SLGE-HEPs (CD144^+^/CD73^--^). Principal component analysis showed clear separation of SLGE-iPSCs (blue dots), SLGE-HEPs (yellow), SLGE-HPCs (orange dots) and CB-HSCs (red dots) ([Figure 6](#fig6){ref-type="fig"}A). Importantly, although SLGE-HPCs formed a separate cluster, they were positioned closest to CB-HSCs, reflecting a gradual differentiation toward HPCs during the protocol. Hierarchical clustering confirmed the overall similarity of SLGE-HPCs and CB-HSC transcriptomes, in contrast to SLGE-iPSCs and SLGE-HEPs ([Figure 6](#fig6){ref-type="fig"}B). Moreover, genes involved in hematopoietic development and HSC function were similarly expressed in SLGE-HPCs and CB-HSCs ([Figure S6](#mmc1){ref-type="supplementary-material"}A). Of note, many genes and TFs ([Figure S6](#mmc1){ref-type="supplementary-material"}A, black arrows) previously used in transdifferentiation settings ([@bib2], [@bib34], [@bib35], [@bib40], [@bib41]) and forward programming approaches ([@bib12]) were expressed at similar levels in SLGE-HPCs and CB-HSCs. Although exogenous SLGE expression was decreased to basal expression levels ([Figure 4](#fig4){ref-type="fig"}C), SLGE-HPCs expressed endogenous *SCL*, *LMO2*, and *GATA2* at physiological levels, similar to CB-HSCs. *ETV2* expression was slightly increased compared with CB-HSCs. However, expression of a number of HSC-associated genes was lacking in SLGE-HPCs. Especially transcriptional regulators with a crucial role in hematopoietic development or HSC homeostasis, such as *HLF* ([@bib13]) or homeobox TF of the *HOXA* ([@bib9], [@bib20]) gene cluster or the HSC surface marker *PROM1*/CD133 were expressed at much lower levels or not expressed in SLGE-HPCs ([Figure 6](#fig6){ref-type="fig"}C). In addition, failure of SLGE-HPCs to silence genes that are repressed or not expressed in CB-HSCs could be crucial for HSC characteristics and functions ([Figure S6](#mmc1){ref-type="supplementary-material"}B). Other genes involved in self-renewal of PSCs (*NANOG*, *POU5F1*, and *SOX2*) were clearly downregulated in SLGE-HPCs ([Figure S6](#mmc1){ref-type="supplementary-material"}C). Direct, pairwise comparison of gene set enrichment analysis ([@bib36]) ([Table S3](#mmc2){ref-type="supplementary-material"}) indicated that the genes that were downregulated in SLGE-HPCs compared with CB-HSPCs were associated with HSC phenotype ([Figure 6](#fig6){ref-type="fig"}D) (yellow dots). Genes enriched in SLGE-HPCs are involved in myeloid (green dots) or erythroid (red dots) differentiation and cell-cycle regulation (purple dots). Particular genes involved in lymphoid differentiation (blue dots) were slightly more enriched in CB-HSCs. The transcriptome analysis supports the *in vitro* lineage potential of SLGE-HPCs and suggests the need for additional up- and/or downregulation of certain TFs or governing regulatory pathways.Figure 6RNA sequencing Comparison between SLGE-iPSC-Derived HEPs/HPCs, and CB-HSCs(A) Principal-component analysis (PCA) for all 22,214 genes over dimensions 1 and 2 with samples colored by groups.(B) Unsupervised heatmap of the top 5% of genes (n = 1,111) with the highest variance. Samples are ordered by hierarchical clustering, with the dendrogram above indicating the sample clustering. Similarity between each sample is equal to the positioning within the hierarchical tree. Genes are subdivided into five main clusters by hierarchical clustering based on similar gene expression.(C) Heatmap of the top 50 protein-coding genes not induced in SLGE-HPCs (mean log~2~FC = −10.1, p~adj~ \< 0.004). Gene ontology (Transcription and Homeobox) based on *DAVID* otherwise in alphabetical order.(D) Gene set enrichment analysis of coordinated gene expression changes in 117 hematopoiesis-associated gene sets ([@bib36]) ([Table S3](#mmc2){ref-type="supplementary-material"}) in SLGE-HPCs and CB-HSCs. Normalized enrichment scores (NES) are plotted against the false discovery rate (FDR). Significant enrichment (FDR \< 0.1) is indicated by the vertical line.

Discussion {#sec3}
==========

iPSC technology and the ability to generate pluripotent cells from patients with diverse hematological diseases offers the opportunity to model various diseases and gain precise information about molecular pathways, transcriptional networks, and ontogenetic processes. However, application of iPSC-derived hematopoietic cells is often restricted by demanding protocols to generate large numbers of HSPCs and terminally differentiated hematopoietic cells in a robust manner. In addition, the output of most protocols is quite variable in terms of quantity, quality, and differentiation status. These limitations restrict the use of iPSC-derived HSPCs for large *in vitro* and *in vivo* experiments, drug screens, and especially possible future clinical applications. The challenge to generate HSPCs from iPSCs is already apparent at the beginning of the differentiation process by the difficulty to generate sufficient amounts of HEPs, which often need to be purified from heterogeneous cell populations before hematopoietic specification.

Here, we established a defined, robust, and efficient protocol based on TF-mediated hemato-endothelial forward programming of hiPSCs by temporally controlled overexpression of *SCL*, *LMO2*, *GATA2*, and *ETV2*. Each of these TFs was identified as a critical regulator for mesodermal, endothelial, and/or hematopoietic specification and their functions were evaluated in animal models ([@bib16], [@bib22], [@bib29], [@bib43]). Interestingly, SCL- and GATA-binding proteins were identified to act synergistically with LMO2 to form a transcriptional *trans*-activating complex that regulates primitive hematopoietic ontogeny in vertebrates ([@bib25]). Similarly, *GATA2* and *ETV2* are co-expressed and interactively regulate early stages of hematopoietic development ([@bib23], [@bib37]). In our gain-of-function screening, we unraveled the functions of these key TFs with regard to early hemato-endothelial specification. We identified *ETV2* as a remarkably potent inducer of endothelial differentiation that produces cells with a predominantly VEC phenotype (CD144^+^/CD73^+^) when expressed alone. However, combination of *ETV2* with *LMO2* or *GATA2* induced the production of HEPs (CD144^+^/CD73^--^). This effect was even more pronounced by combined overexpression of *SCL/GATA2/ETV2* or *SCL/LMO2/GATA2/ETV2*. Although this study focused on the four-factor combination *SCL*/*LMO2*/*GATA2*/*ETV2*, the differences in induction of HEPs between this combination and the three-factor combination *SCL*/*GATA2*/*ETV2* were not significant ([Figure 1](#fig1){ref-type="fig"}D). Thus, the exogenous expression of *LMO2* might not be essential for HEP specification. Endogenous LMO2 might be sufficient to facilitate formation of complexes and protein-protein interactions of the overexpressed TFs ([@bib38]). As the role of *LMO2* during the differentiation process is not entirely clear, this should be explored in future studies. However, this screening experiment identified the combination *SCL/LMO2/GATA2/ETV2* to be highly potent for specific and robust angio-hematopoietic specification of iPSCs. The combinatorial effect of SLGE-mediated forward programming and cytokine-based directed differentiation efficiently generated SLGE-HEPs. The cytokines, used during phase I, supported the formation of SLGE-HEPs while preventing VEC specification ([Figure S2](#mmc1){ref-type="supplementary-material"}C). Mesodermal priming by CHIR seemed not to be the most essential component for efficient SLGE-HEP generation ([Figure S2](#mmc1){ref-type="supplementary-material"}C), which might be compensated by SLGE overexpression.

We hypothesize that the four TFs in our system act synergistically in one regulatory complex and contribute to one gene regulatory network. The combination of murine *Erg* (such as the *ETV2* member of the ETS TF family), *Gata2*, *Lmo2*, *Runx1c*, and *Scl* was previously used to reprogram murine fibroblasts into HPCs with short-term engraftment and multi-lineage potential ([@bib2]). A gain-of-function screen to evaluate TFs identified *GATA2* and *ETV2* as crucial TFs for hematopoietic induction. Constitutive overexpression of *GATA2* and *ETV2* directly induced endothelium with hematopoietic, pan-myeloid potential, but without engraftment ([@bib12]). In contrast to these approaches, our SLGE-based forward programming protocol is fully inducible and requires overexpression of TF only for a short period to rapidly generate large numbers of highly pure SLGE-HEPs without effecting the HPC production. Although SLGE-HEPs expressed CD43, an early marker of hematopoietic commitment ([@bib42]), they are not fully committed to hematopoietic lineages. SLGE-HEPs were still capable to mature into adherent cells with VEC phenotype (CD144^+^/CD73^+^/CD34^+^/CD45^--^) under endothelial conditions. Importantly, SLGE-HEPs undergo EHT and produce hematopoietic cells with an HSC-like phenotype, which proceeds in the absence and without the influence of ectopic SLGE expression. The expression of early mesodermal markers (e.g., *EOMES*, *MESP1*, *MIXL1*, and *T*), differentiation into KDR^+^ cells, subsequent endothelial specification (CD144 expression), EHT, and finally generation of CD45^+^/CD34^+^ SLGE-HPCs, suggests that the SLGE-based forward programming recapitulates early stages of embryonic hematopoiesis and mimics important developmental stages *in vitro*. Thus, this protocol----and the large quantity of HEPs and HPCs generated----offers a robust basis to decipher early developmental processes and may help to identify additional gene regulatory networks that directly alter mesodermal specification, HE development, the EHT process, and generation of fully functional HSPCs. Despite all attempts, *de novo* generation of *bona fide* human HSPCs *in vitro* is still challenging and currently relies on genetic modifications of HE cells with up to seven exogenous TFs ([@bib40]). However, this procedure requires the generation of large amounts of iPSC-derived HE for genetic modification and modified HE cells gain their HSPC-like potential *in vivo* only after direct injection into the bone marrow of recipient mice. Our SLGE-iPSC-derived HPCs share some HSPC characteristics, but generally exhibit a rather predominant erythro-megakaryocytic and myeloid potential, and a restricted lymphoid lineage potential with a limited proliferative potential at the HPC level and only short-term persistence after transplantation into recipient mice. In addition, the predominant expression of embryonic and fetal hemoglobin and a minor expression of adult globin indicate a primitive hematopoietic phenotype of the majority of SLGE-HPCs. This might be attributed to a rather primitive hematopoietic capacity of generated HEPs with the current protocol, but may also indicate functional heterogeneity of SLGE-HEPs regarding definitive hematopoietic potential. HE heterogeneity can be attributed to early mesodermal specification and depends, among other factors, on Wnt-β-catenin and activin-nodal signaling ([@bib39]). Activation of an arterial program through overexpression of the TF *ETS1* in HE promoted a definitive, arterial hematopoietic program with T- and B-lymphoid potential. *ETS1* and *ETV2* belong to the same ETS TF family and have a highly conserved DNA binding domain (ETS domain). ETS TFs play an important role in regulation of endothelial genes ([@bib18]) and later in HSC specification and maintenance ([@bib24]). Regulation of different endothelial genes and diverse primitive and definitive HE genes might be orchestrated by different ETS transcriptional regulators or a combination of factors, respectively. Ectopic expression of *ETS1* in addition to SLGE or the exchange of *ETV2* for *ETS1* may induce a more arterial/definitive HE type and induce a rather definitive hematopoietic progenitor phenotype. Despite the assumption of the primitive polarization of our SLGE-HEPs, the newly produced SLGE-HPCs exhibited an HSC surface marker signature found in CB-HSCs and adult bone marrow HSCs (CD45^+^/CD34^+^/CD38^--^/CD45RA^−^/CD90^+^/CD49f^+^). Interestingly, our RNA sequencing data demonstrated that SLGE-iPSC-derived HEP/HPCs and CB-HSCs share a high degree of overlap in common hematopoietic and especially HSC gene expression. Of note, many TFs used in forced differentiation ([@bib2], [@bib10], [@bib34], [@bib40]) and transdifferentiation protocols ([@bib35]) are expressed in SLGE-iPSC-derived HEP/HPCs. However, major differences were also noted and gene set enrichment analysis revealed enrichment of myeloid and erythroid genes in SLGE-iPSC-derived HPCs. The lack of crucial hematopoietic TFs may explain the absence of long-term engraftment of our SLGE-HPCs. In particular, SLGE-iPSC-derived HPCs exhibited lower expression of the *HOXA* gene cluster, which was described to facilitate HSC function and self-renewal *in vivo* ([@bib20]). Defective medial *HOXA* gene activation was previously observed in ESC-derived HSPCs and was described to be a crucial developmental barrier to establish ESC-derived HSCs with self-renewal potential ([@bib9]). The *HOXA* family was also implicated in HSPC specification in other examples of forced differentiation and transdifferentiation. The combinatorial expression of *HOXA9* and other transcriptional regulators converted hPSC-derived myeloid-restricted precursor cells into multi-lineage HSPCs ([@bib10]) or conferred multi-lineage engraftment potential to undirected differentiated HE as one of the abovementioned seven TFs (*ERG*, *HOXA5*, *HOXA9*, *HOXA10*, *LCOR*, *RUNX1* and *SPI1*) ([@bib40]). Thus, activation of the *HOXA* gene cluster and/or ectopic overexpression of *HOXA* genes may govern hematopoietic fate determination in the HEP state and confer self-renewal potential to SLGE-HPCs. Despite some differences between SLGE-HPCs and *bona fide* HSCs, our described platform provides a powerful tool to generate sufficient numbers of HEPs for large screening experiments. This will help to identify combinations of synergistically acting TF and signaling pathways that govern early hematopoietic development (e.g., mesoderm specification and arterial endothelial development). Furthermore, our current protocol overcomes the limitation of producing pure fractions and high numbers of HEPs and HPCs as a single 12-well of initially seeded SLGE-iPSCs routinely generated ∼4.5 × 10^6^ SLGE-HEPs and ∼7 × 10^6^ (CD45^+^/CD34^+^) SLGE-HPCs in only 11 days. Therefore, we propose that this system can also be utilized to establish new hematological disease models and perform drug screening or gene therapy approaches to discover and establish new suitable treatment options.

Experimental Procedures {#sec4}
=======================

Design of the Inducible Vector System {#sec4.1}
-------------------------------------

Coding sequences for human TF *SCL* (GenBank: [M61108.1](ncbi-n:M61108.1){#intref0010}), *LMO2* (GenBank: [BC035607.1](ncbi-n:BC035607.1){#intref0015}), *GATA2* (GenBank: [M68891.1](ncbi-n:M68891.1){#intref0020}), and *ETV2* (*ETV2* codon-optimized) (GenBank: [NM_014209.3](ncbi-n:NM_014209.3){#intref0025}) were cloned into previously described tet-inducible, third-generation SIN-lentiviral vectors ([@bib14]), which co-expressed the transactivator rtTA.M2 (M2) in an all-in-one design. TF cassettes were arranged in a monocistronic or bicistronic configuration to generate the vectors as shown in [Figure 1](#fig1){ref-type="fig"}A. Expression of TFs was driven and regulated by a tet-inducible (T11) promoter and bicistronic expression was achieved using self-cleaving 2A-peptides (T2A or E2A). To enable positive selection of transduced cells, P2A-puromycin (Puro) or P2A-zeocin (Zeo) selection marker cassettes were inserted in frame, downstream of the M2 transactivator and constitutively expressed by the human PGK promoter (cloning details are available upon request).

Directed Hemato-endothelial Differentiation {#sec4.2}
-------------------------------------------

Genetically modified human SLGE-iPSCs were seeded at a density of 1 × 10^6^ cells per 9-cm^2^ culture dish in conditioned iPSC medium (or StemMACS iPS-Brew XF stem cell medium) containing 10 μM Y-27632 on day −3. After 3 days, medium was changed to RPMI medium (PAN Biotech), supplemented with 100 U mL^−1^ penicillin, 100 μg mL^−1^ streptomycin (PAN Biotech), 0.5% non-essential amino acids (Gibco) and 2% B27 supplement without insulin (Gibco) (RB27^--^). This point of differentiation was considered as day 0 and as initiation of phase I ([Figure 1](#fig1){ref-type="fig"}A). Cells were sequentially cultivated with small molecules and recombinant cytokines in the following order: day 0: RB27^--^ medium containing 8 μM CHIR99021 (Axon Medchem, Groningen, the Netherlands); day 1: RB27^--^ supplemented with 1 μg mL^−1^ Dox (Sigma-Aldrich) to induce SLGE; days 2--7: StemPro34 SFM (Thermo Fisher Scientific), 100 U mL^−1^ penicillin, 100 μg mL^−1^ streptomycin, 1 μg mL^−1^ Dox, 6 μM SB431542 (Leibniz University Hannover), 100 ng mL^−1^ SCF, 20 ng mL^−1^ FGF2, 50 ng mL^−1^ TPO, 15 ng mL^−1^ VEGF, 25 ng mL^−1^ IL-3 (all Peprotech, Hamburg, Germany). On day 7 of differentiation and the end of phase I, SLGE-HEPs were dissociated with Accutase and seeded for phase II ([Figure 3](#fig3){ref-type="fig"}A). Hematopoietic specification was accomplished on 0.1% gelatin (Sigma-Aldrich)-coated cell culture dishes, at a density of 2.5 × 10^6^ cells per 9-cm^2^ culture dish in STEMdiff APEL 2 (STEMCELL Technologies, Cologne, Germany) supplemented with 100 U mL^−1^ penicillin, 100 μg mL^−1^ streptomycin, 100 ng mL^−1^ SCF, 20 ng mL^−1^ FGF2, 50 ng mL^−1^ TPO, 100 ng mL^−1^ FLT3L, 25 ng mL^−1^ IL-3 (all Peprotech) without Dox for hematopoietic differentiation (start of phase II). Cells were cultivated in this medium for 5 days (day 11 of differentiation) to generate SLGE-HPCs. Additional experimental procedures are provided in [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.
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